Salem Radio Network News Tuesday, March 21, 2023


Trial data supports Pfizer’s COVID drug for high-risk adults -FDA staff

(Reuters) – Trial results for Pfizer Inc’s antiviral pill, Paxlovid, supported its use to treat mild-to-moderate COVID-19 in adults at high-risk of severe disease, staff reviewers at the Food and Drug Administration said on Tuesday.

The comments were made in the regulator’s briefing documents ahead of a meeting of the FDA’s external advisers on Thursday to discuss a possible full approval for Pfizer’s oral pill, which has been cleared for emergency use since late 2021.

(Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber)


Editorial Cartoons

View More »

Bob Gorrell
Wed, Mar 15, 2023